Forbes April 11, 2022
Robert Hart

Topline

German biotech BioNTech on Monday highlighted compelling preliminary data from a clinical trial evaluating a new mRNA-based cancer therapy, an early indication the technology behind some of the most effective Covid-19 vaccines could potentially unlock new treatments for cancer as well as targeting other infectious diseases.

Key Facts

What We Don’t Know

Whether the treatment works. There is not enough data to properly evaluate how effective this new treatment combination might be, if at all. It is also possible new safety issues and side effects could emerge in larger, longer trials. Only a few of the patients in the trial—five, or around a third—were actually given the CARVac vaccine, and more data will be needed to demonstrate its role...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development
3 Ways The New Administration Could Speed The Path To New Medicines
Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court
Dear President-Elect Trump: To Reach The Next Cure, Fix These Policies
The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery

Share This Article